In sum, our results suggest that incorporating small-molecule inhibitors of DNA-PK and MEK1/2-ERK1/2 pathways may alleviate intrinsic and extrinsic resistance to chemotherapy agents, respectively, thereby enhancing the efficacy of chemotherapy regimens and improving clinical outcomes for pediatric AML patients. Here, MAP2K1 is linked to acute myeloid leukemia.